Novartis, the Swiss Pharmaceutical giant, has confirmed a $15 million investment in Gamida Cell, a company that develops stem cell therapies. Novartis had already invested $35 million in Gamida Cell, taking their total investment to $50 million, however the latest investment?will be partially directed towards the development?of NiCord,?an?evolving therapy?used to treat?high-risk blood?malignancies, blood?cancers such?lymphoma and leukemia, and sickle cell disease.
Grace Century CEO and Director of Research Scott Wolf commented ?This confirms what we have started to see in the beginning of this year with AMG acquiring Cord Blood registry, One of the world?s largest Cords Blood banks. The Pharma companies want a stake in stem cells?
